EFFECT OF METFORMIN THERAPY ON PLASMA ADIPONECTIN IN OBESITY WITH PREDIABETES PATIENTS

manaf, asman and Karimi, Jazil and Deswita, Sri and Syahbuddin, Syafril and Decroli, Eva (2010) EFFECT OF METFORMIN THERAPY ON PLASMA ADIPONECTIN IN OBESITY WITH PREDIABETES PATIENTS. (Unpublished)

PDF Download (443Kb)

Abstract

Objectives :We investigated the effect of metformin on adiponectin plasma in obesity with prediabetes patients, in connection with fasting plasma glucose, 2 –h post prandial,,lipid profile, BMI and waist circumference. Methods: a clinical trial with 40 obesity-prediabetes, 30 received metformin 500 mg twice daily and other received placebo as control. Adiponectin level,fasting plasma glucose, 2-h post prandial, lipid profile, BMI and waist circumference was measured at beginning and after 12 weeks. Statistic analysis by using software SPPSS 12 for windows. Results : adiponectin level significantly increased (3.56 ± 1.35 to 4.90 ±2.24 ug/ml, p= 0.002), in line with significant decreased of fasting plasma glucose (102.63±20.3 to 96.57±14.17 mg/dl,p=0.045), 2-h post prandial (167.03±15.79 to 134.70 ±21.54 mg/dl,p=0.042),trigliseride (164.93 ±55.42 to 125.03 ±32.98 mg/dl,p=0.000), no significant decreased LDL-Chol (148.41± 45.32 to 145.53± 40.22 mg/dl,p=0.295 ), increased HDL-Chol (47.20± 9.10 to 56.63 ± 10.56 mg/dl,p=0.000), decreased waist circumference (94.17±17.0 to 92.40±7.39 cm,p=0.005 ) and BMI (29.02± 1.88 to 27.89 ± 2.11 kg/m2,p=0.000). Conclusion: metformin remarkably increased adiponectine level and HDL-Chol significantly, decreased significantly another variable except LDL-Chol and Blood pressure. Keywords : metformin, adiponectine and obesity with prediabetes

Actions (login required)

View Item